Chikazawa K, Netsu S, Konno R
Eur J Gynaecol Oncol. 2016 Aug;37(4):511-516.
To determine if concurrent chemoradiotherapy (CCRT) with paclitaxel and carboplatin is effective, convenient, and tolerable for cervical cancer treatment.
The authors retrospectively reviewed the medical records of 49 patients. Primary outcomes included progression-free survival (PFS) and overall survival (OS). The Cox proportional hazards model was adjusted for all prognostic factors in the multivariable analysis.
Over the median follow-up time of 32 months in a sample consisting of 87.8% (43/49) squamous cell carcinoma and 12.2% (6/49) adenocarcinoma, two-year PFS and OS rates were 67.2% and 80.9%, respectively. In univariate analyses, stage, histology, performance status, tumor size, and age were significant vari- ables for OS; only histology was significant in the multivariable analysis. Acute toxicity grade 3 or 4 neutropenia (85.7%), diarrhea (32.7%), and late toxicity grade 3 or 4 (12.2%) were detected.
For cervical cancer treatment, CCRT with paclitaxel/car- boplatin is satisfactory.
确定紫杉醇和顺铂同步放化疗（CCRT）治疗宫颈癌是否有效、便捷且耐受性良好。
作者回顾性分析了49例患者的病历。主要结局包括无进展生存期（PFS）和总生存期（OS）。在多变量分析中，采用Cox比例风险模型对所有预后因素进行校正。
在中位随访时间32个月的样本中，87.8%（43/49）为鳞状细胞癌，12.2%（6/49）为腺癌，两年PFS率和OS率分别为67.2%和80.9%。单变量分析中，分期、组织学类型、体能状态、肿瘤大小和年龄是OS的显著变量；多变量分析中只有组织学类型具有显著性。检测到3或4级急性毒性中性粒细胞减少（85.7%）、腹泻（32.7%）以及3或4级晚期毒性（12.2%）。
对于宫颈癌治疗，紫杉醇/顺铂同步放化疗效果良好。
